Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies

⿢We report a post-hoc analysis examining the efficacy of BRV 50⿿200mg/day on SGTCS.⿢BRV was associated with 61.2⿿82.1% median reduction in baseline SGTCS vs 33.3% PBO.⿢A ⿥50% responder rate was reported in 55.0⿿64.0% of patients on BRV vs 33.0% PBO.⿢Complete SGTCS freedom was reported in 22.6⿿36.0% of patients on BRV vs 14.8% PBO.⿢BRV was well tolerated, with an AE profile similar to the overall pooled population.